Trade Bristol Myers ^BMY

Bristol Myers Squibb Company $BMY Stock: Pzena Investment Management LLC Lowers Holdings

Bristol Myers Squibb Company $BMY Shares Sold by AIA Group Ltd

48,234 Shares in Bristol Myers Squibb Company $BMY Acquired by Associated Banc Corp

An information-theoretic framework for inferring T cell dynamics from single-cell RNA and T cell receptor sequencing

Bristol Myers Squibb Canada Partners with TANK Worldwide and Ogilvy Health to Turn Autumn Leaves into a Guide for Spotting the Warning Signs of Melanoma

Head-To-Head Contrast: Bristol Myers Squibb (BMY) & Its Peers - Zolmax

Bristol Myers Squibb Company $BMY Stock Holdings Raised by Rakuten Investment Management Inc.

Bristol Myers Squibb Shares Rose Even As Profit Fell

Bausch Health Cos (NYSE:BHC) & Bristol Myers Squibb (NYSE:BMY) Head-To-Head Comparison - Markets Daily

Analyzing Bristol Myers Squibb (NYSE:BMY) and Bausch Health Cos (NYSE:BHC) - Stock Observer

Why Tempus AI Stock Is Up 8.7% And What's Next

Bristol Myers Squibb Company $BMY Shares Newly Purchased by VCI Wealth Management LLC

Bristol Myers Squibb (NYSE:BMY) Stock Price Breaks Above 50 Day Moving Average on Analyst Downgrade - Stock Observer

Reply to: 'Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer'

Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials

5 must-read analyst questions from Bristol-Myers Squibb's Q3 earnings call

TEM Stock Jumps On Upbeat Revenue, Raised Outlook - Cathie Wood's ARK Buys Over 154K Shares Ahead Of Earnings

43 ETFs Add to Bristol-Myers Squibb (BMY) on Oct. 29

Bank Julius Baer & Co. Ltd Zurich Purchases 73,200 Shares of Bristol Myers Squibb Company $BMY

18,717 Bristol Myers Squibb Company $BMY Shares Purchased by Profund Advisors LLC - Stock Observer

Bristol Myers Squibb (NYSE:BMY) Stock Gets Price Target Trim from Morgan Stanley - Zolmax

Bristol Myers Squibb Company $BMY Stock: Heritage Investors Management Corp Cuts Position - Daily Political

Learn Why The Bull Case For Bristol Myers Squibb Stock Could Change Following Earnings Beat

Molecular and immune heterogeneity across limited-stage and extensive-stage small cell lung cancer

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Mirae Asset Global Investments Co. Ltd. Makes New Investment in Bristol Myers Squibb Company $BMY

Sumitomo Mitsui Trust Group Inc. Sells 19,128 Shares of Bristol Myers Squibb Company $BMY - Daily Political

Hengrui's third-quarter profit rebounds on out-licensing revenue

Why Everyone Is Watching Bristol-Myers Squibb (BMY) Today

What Bristol Myers Squibb Stock's Earnings Beat Means For Shareholders

Bristol Myers Squibb Company $BMY Stock Bought by Americana Partners LLC - Markets Daily

Bristol Myers Squibb Company $BMY Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al

Birinyi Associates Inc. Purchases New Position in Bristol Myers Squibb Company $BMY

Americana Partners LLC Acquires 46,008 Shares of Bristol Myers Squibb Company $BMY - Stock Observer

Bristol Myers Squibb Company $BMY Stock Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - Stock Observer

Bristol Myers Squibb (NYSE:BMY) Stock Price Target Cut by Morgan Stanley - Stock Observer

Is Bristol-Myers Squibb (BMY) Stock Cheap, Or Are Risks Priced In?

Bristol Myers Squibb Q3 Earnings Call Highlights

Head and Neck Squamous Cell Carcinoma Market Size in the 7MM is projected to reach nearly USD 2,560 million by 2036, growing at a CAGR of 10.5% during 2026-2036 | DelveInsight | ABNewswire

Neuroendocrine Prostate Cancer Market and Pipeline Appear Robust With Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | ABNewswire

Bristol Myers Squibb (NYSE:BMY) Posts Earnings Results, Beats Expectations By $0.25 EPS

AI CRM Adoption Could Be A Key Catalyst For Veeva Systems Stock (VEEV)

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue

BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook

Bristol-Myers Squibb Slashes FY26 EPS Outlook, But Raises Revenue Forecast - Update

Bristol Myers Squibb Raises Fiscal Year Outlook as 3Q Revenue Rises | Morningstar

Bristol Myers Squibb Co. Q3 Income Retreats

Bristol-Myers Squibb Beat Estimates but Cut EPS Guidance in Q3 2026

Clinical risk factors alone do not predict the development of moderate-severe chronic graft-versus-host disease after hematopoietic cell transplantation and post-transplant cyclophosphamide

Enhanced cfDNA methylation profiling by detection and correction of jagged ends

Anthropic acquires one-person biotech startup that used Claude to develop promising muscular dystrophy treatment in 18 months

Anthropic buys a one-person biotech and starts its own drug programmes

Bristol Myers Squibb Company $BMY Stock: Roman Butler Fullerton & Co. Trims Holdings

Cardiff Names Alland Interim Medical Chief Ahead Of Planned Phase 3 Cancer Trial

FY2026 Earnings Estimate for BMY Issued By Erste Group Bank - Stock Observer

KKR Invests $475 Million in Alexandria Real Estate Equities' Campus Point | Valuespectrum.com

Bristol Myers Squibb (BMY) Stock Fair Value Edges Lower On Split Analyst Views

Bristol Myers Squibb (BMY) Stock Still Looks Reasonable Below Fair Value

Bristol Myers Squibb Company $BMY Stock Purchased by Simplicity Wealth LLC - Markets Daily

Leo Wealth LLC Purchases 39,189 Shares of Bristol Myers Squibb Company $BMY

Vamsi Tekuru Appointed Managing Director of Bristol Myers Squibb India, ETGCC

Bristol Myers Squibb Company $BMY Stock: Arnhold LLC Decreases Position

BMY Stock Rises on Trial Data, With Implications for EXEL

Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?

RiskVantage AI Unveils Explainable, Sovereign AI for the $75 Billion Contract and Deal Legal Market at Dubai AI Festival

3 Blue-Chip Dividend Stocks That Show Why Roth IRA Income Can Be Worth More

Bristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Bristol Myers Squibb (NYSE:BMY) Given New $78.00 Price Target at Piper Sandler

ChatGPT Enterprise vs Microsoft 365 Copilot 2026: Pricing, Customer Results and Top 10 Enterprise AI Platforms

BioNTech, Bristol Myers' Pumitamig Shows 36.7% Response Rate In Phase 2 NSCLC Trial

Citizens Financial Group Inc. RI Buys 44,768 Shares of Bristol Myers Squibb Company $BMY

Tempus AI's (TEM) Buy Rating Reiterated at Needham & Company LLC - Zolmax

Bristol Myers Squibb Company $BMY Stake Lessened by Lantern Wealth Advisors LLC - Zolmax

Bristol Myers Squibb Company $BMY Stock Position Decreased by Lantern Wealth Advisors LLC - Markets Daily

Bristol Myers Squibb Company $BMY Shares Acquired by Brookstone Capital Management

The Call Bristol-Myers Squibb Bulls Got Right

Bristol Myers Squibb Reports Patient Death in MS CAR-T Therapy Trial, ETPharma

31,873 Tempus AI, Inc. $TEM Shares Acquired by Washington Trust Advisors Inc.

Bristol Myers Squibb (NYSE:BMY) Cut to "Hold" at Zacks Research

Bristol Myers Squibb (NYSE:BMY) Downgraded by Zacks Research to Hold - Stock Observer

Tempus AI, Inc. $TEM Shares Bought by Washington Trust Advisors Inc. - Stock Observer

Bristol Myers Squibb (NYSE:BMY) & Astellas Pharma (OTCMKTS:ALPMY) Financial Analysis - Daily Political

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Tempus AI (NASDAQ:TEM) Stock Rating Reaffirmed as Buy by Needham & Company LLC - Markets Daily

Tempus AI's (TEM) "Buy" Rating Reiterated at Needham & Company LLC - Markets Daily

Bristol Myers Squibb Moves On Two Fronts: MS Cell Therapy Data And Tempus AI Expansion; Stock Down

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Fifth edition of MCADDI 2026 to be held at University of Hyderabad from October 25

Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals | Morningstar

Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 | Morningstar

Tempus AI (NASDAQ:TEM) Stock Rating Reaffirmed as "Buy" by Needham & Company LLC - Stock Observer

Tempus AI (NASDAQ:TEM) Earns Buy Rating from Needham & Company LLC - Stock Observer